表紙:ベータ遮断薬の世界市場:2021-2028年
市場調査レポート
商品コード
1058831

ベータ遮断薬の世界市場:2021-2028年

Global Beta Blockers Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 185 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
ベータ遮断薬の世界市場:2021-2028年
出版日: 2022年02月16日
発行: DataM Intelligence
ページ情報: 英文 185 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のベータ遮断薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制・償還環境、市場規模の推移・予測、タイプ・適応症・流通経路・地域/主要国など各種区分別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 世界のベータ遮断薬市場:調査手法・調査範囲

第2章 世界のベータ遮断薬市場:市場の定義と概要

第3章 世界のベータ遮断薬市場:エグゼクティブサマリー

第4章 世界のベータ遮断薬市場:市場力学

  • 市場影響要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界のベータ遮断薬市場:産業分析

  • ポーターのファイブフォース分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 世界のベータ遮断薬市場:COVID-19の分析

  • 市場でのCOVID-19の分析
  • COVID-19における価格ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関する政府のイニシアチブ
  • 製造業者の戦略的イニシアチブ
  • 総論

第7章 世界のベータ遮断薬市場:タイプ別

  • 非選択的ベータ遮断薬
    • プロプラノロール (Inderal)
    • ナドロール (CorGard)
    • ピンドロール (Visken)
    • ペンブトロール (Levatol)
    • ソタロール (Betapace)
    • その他
  • 選択的ベータ遮断薬
    • アテノロール
    • ベタキソロール
    • エスモロール
    • ネビボロール
    • その他

第8章 世界のベータ遮断薬市場:適応症別

  • 狭心症
  • 心不全
  • 高血圧
  • その他

第9章 世界のベータ遮断薬市場:流通経路別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 世界のベータ遮断薬市場:地域別

  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第11章 世界のベータ遮断薬市場:競合情勢

  • 主な展開・戦略
  • 企業シェア分析
  • 製品ベンチマーキング
  • 注目の主要企業のリスト

第12章 世界のベータ遮断薬市場:企業プロファイル概要

  • Pfizer
  • Neon Healthcare
  • Novartis
  • Mercury Laboratories Ltd.
  • Bayer HealthCare Pharmaceuticals Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Midas Pharma GmbH
  • Global Calcium PVT LTD
  • Baxter
  • AbbVie Inc.

第13章 世界のベータ遮断薬市場:DataM

目次
Product Code: DMPH4688

Market Overview

The global beta blockers market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Beta blockers, also known as beta-adrenergic blocking agents, reduce blood pressure. It is used to prevent, deal with or improve symptoms in people who've abnormal coronary heart rhythm (arrhythmia), coronary heart failure, Chest ache (angina), coronary heart assaults, Migraine, sure varieties of tremors. It works by blocking the effects of the hormone epinephrine, also known as adrenaline.

Market Dynamics

The increasing prevalence of hypertension in the geriatric population is expected to drive market growth.

According to the American College of Cardiology, Older adults are generally undertreated for high blood pressure, despite having the highest prevalence of hypertension and the highest risk of CV morbidity and mortality (BP). Hypertension is a major modifiable risk factor for cardiovascular disease (CVD), and its prevalence and severity rise with age. According to the National Health and Nutrition Examination Survey (NHANES) in the United States, hypertension affects 70% of persons over 65. As our population ages, this figure will continue to rise. In 2014, 15% of the US population was 65 years old, and that number is predicted to rise to 20% by 2050. Moreover, huge investment in R&D, high prevalence and incidence of cardiovascular diseases have increased the demand for beta blockers drugs due to which the market is expected to drive in the forecast period.

Restraint:

Along with its needed effects, a medicine may cause some unwanted effects. Beta-blockers slowdown heart rate. This can trigger symptoms associated with low blood pressure (hypotension). In addition, it includes an upset stomach, nausea, diarrhea or constipation, and some people report erectile dysfunction when taking beta-blockers. This is a common side effect with medications that lower blood pressure. These are some factors that the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Hypertension is one of the most common morbidities in COVID-19. Beta-blockers are widely used as one of the most common antihypertensive agents. It reduces the risk of proarrhythmia by suppressing sympathetic-mediated triggers, the functioning reentrant substrate, and the rates of the SA and AV nodes. In addition to this main benefit, as beta-adrenergic blockers, these drugs can block the gate of SARS-CoV-2 entry through negative regulation on the juxtaglomerular cells in the kidneys, reducing the activity of both arms of the RAAS pathway, thus lowering the ACE2 levels. Moreover, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the market will undergo impetus during the forecast period.

Segment Analysis

Nonselective Agents segment is expected to hold the largest market share in beta blockers market.

The non-selective agents' segment accounted for the largest market share in 2020. Non-selective beta-blockers block B1 receptors beta-2 (B2) receptors in the body. These receptors affect how tight or relaxed blood vessels and airways are. Some non-selective beta-blockers can also have alpha-blocking effects. These have a larger effect on lowering blood pressure. For instance, it includes Propranolol (Inderal), Nadolol (CorGard), Pindolol (Visken), Penbutolol (Levatol), Sotalol (Betapace) and Others.

Moreover, some beta-blockers also come in combination tablets or eye drops, where the beta-blocker is combined with another type of medication that treats the same condition, and three beta-blockers are best for heart failure: carvedilol, metoprolol succinate (the long-acting form of metoprolol), and bisoprolol. These beta-blockers have been shown to lower your risk of dying from heart failure complications. Thus, the market is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global beta blockers market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of cardiovascular diseases, huge investment in R&D, increasing aged population, well-established infrastructure and increased demand for beta-blockers drugs are some factors that the market is expected to boost in the forecast period. For instance, According to the American Heart Association, heart disease and stroke are caused by unhealthy diets, physical inactivity, tobacco use, and harmful alcohol usage. Individuals may experience high blood pressure, high blood glucose, high blood lipids, and overweight or obesity due to behavioral risk factors. Twice as many people died in 2020 of heart disease (690,8820 as from COVID-19 (345,323). This doesn't even include another 159,150 who died from a stroke and another 106,106 from diabetes (mostly type 2), which have the same risk factors as heart disease. Heart disease deaths increased by 4.8%, the largest increase in heart disease deaths since 2012. Therefore, it has increased the demand for beta blockers, due to which the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the beta blockers market are Pfizer, Neon Healthcare , Novartis, Mercury Laboratories Ltd., Bayer HealthCare Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Midas Pharma GmbH , Global Calcium PVT LTD, Baxter and AbbVie Inc.

Bayer HealthCare Pharmaceuticals Inc.:

Bayer is a German multinational pharmaceutical and Life Sciences Company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's business areas include pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The Pharmaceuticals division of Bayer focuses on prescription products for women's healthcare, cardiology, oncology, hematology and ophthalmology. The division also comprises the Radiology Business Unit, which markets contrast-enhanced diagnostic imaging equipment and the necessary contrast agents. Moreover, in 2020, the Bayer Group comprised 385 consolidated companies in 83 countries, and in 2020 alone, the company invested nearly €2 billion in research and development.

Product Portfolio:

Why Purchase the Report?

Visualize the composition of the global beta blockers market segmentation by type, indication, distribution channel and region highlighting the key commercial assets and players.

Identify commercial opportunities in global beta blockers market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global beta blockers market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global beta blockers market report would provide an access to an approx.45+ market data table, 40+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Beta Blockers Market - By Type

Nonselective Agents

Propranolol (Inderal)

Nadolol (CorGard)

Pindolol (Visken)

Penbutolol (Levatol)

Sotalol (Betapace)

Others

Selective Agnets

Atenolol

Betaxolol

Esmolol

Nebivolol

Others

Global Beta Blockers Market - By Indication

Angina Pectoris

Heart Failure

High Blood Pressure

Others

Global Beta Blockers Market - By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Global Beta Blockers Market - By Region

North America

South America

Europe

Asia Pacific

Middle East & Africa

Table of Contents

1. Global Beta Blockers Market - Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Beta Blockers Market - Market Definition and Overview

3. Global Beta Blockers Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Indication
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Beta Blockers Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of hypertension in the geriatric population is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the beta blockers drugs are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Beta Blockers Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Reimbursement Analysis
  • 5.4. Unmet Needs

6. Global Beta Blockers Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Beta Blockers Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Nonselective Agents*
    • 7.2.1. Propranolol (Inderal)
    • 7.2.2. Nadolol (CorGard)
    • 7.2.3. Pindolol (Visken)
    • 7.2.4. Penbutolol (Levatol)
    • 7.2.5. Sotalol (Betapace)
    • 7.2.6. Others
    • 7.2.7. Introduction
    • 7.2.8. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Selective Agents
    • 7.3.1. Atenolol
    • 7.3.2. Betaxolol
    • 7.3.3. Esmolol
    • 7.3.4. Nebivolol
    • 7.3.5. Others

8. Global Beta Blockers Market - By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication Segment
  • 8.2. Angina Pectoris*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Heart Failure
  • 8.4. High Blood Pressure
  • 8.5. Others

9. Global Beta Blockers Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy

10. Global Beta Blockers Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Beta Blockers Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Global Beta Blockers Market- Company Profiles

  • 12.1. Pfizer*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Neon Healthcare
  • 12.3. Novartis
  • 12.4. Mercury Laboratories Ltd.
  • 12.5. Bayer HealthCare Pharmaceuticals Inc.
  • 12.6. Teva Pharmaceuticals USA, Inc.
  • 12.7. Midas Pharma GmbH
  • 12.8. Global Calcium PVT LTD
  • 12.9. Baxter
  • 12.10. AbbVie Inc.

LIST NOT EXHAUSTIVE

13. Global Beta Blockers Market - DataM

  • 13.1. Appendix
  • 13.2. About Us
  • 13.3. Contact Us